Author

Mizuki Ariga

Observed names: M., Ariga, MIZUKI ARIGA

Institution: Fujita Health University

Observed institutions: Fujita Health University, Fujita Health University Okazaki Medical Center

OpenAlex ID: A5111293237

Clinical Outcomes of Cabozantinib in Patients Previously Treated with Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma—Importance of Good Liver Function and Good Performance Status

2023 · Teiji Kuzuya, Naoto Kawabe, et al. · Cancers · 17

Biomarker-Based Responder Selection and Early Prediction of Treatment Response in Hepatocellular Carcinoma: Dynamic Changes in Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin During Atezolizumab Plus Bevacizumab Therapy

2025 · Teiji Kuzuya, Hisanori Muto, et al. · Cancers · 4

Efficacy of Second-line Lenvatinib for Hepatocellular Carcinoma After Early Progression on Atezolizumab–Bevacizumab

2026 · HISANORI MUTO, TEIJI KUZUYA, et al. · Anticancer Research · 1

The Central Role of Liver Function at Treatment Initiation and Its Preservation at Progression for Post-Progression Survival After Atezolizumab Plus Bevacizumab in Advanced Hepatocellular Carcinoma

2026 · Mizuki Ariga, Teiji Kuzuya, et al. · Biomedicines · 1

Amber-red color imaging makes the dissection line more evident during gastric endoscopic submucosal dissection

2025 · Kohei Funasaka, Ryoji Miyahara, et al. · Endoscopy International Open · 1

Systemic therapy sequence and outcomes in unresectable hepatocellular carcinoma: results from the multicenter Tokai Post ICI Sequential Therapy Registry cohort

2026 · Mone Tsukimoto, Naoto Fujiwara, et al. · European Journal of Gastroenterology & Hepatology

Supplementary Material for: Diagnostic Pathways and Outcomes of First-Line Atezolizumab plus Bevacizumab in Patients with Locoregional Therapy–Ineligible Hepatocellular Carcinoma at Initial Diagnosis

2026 · karger, figshare admin, G., Komura, et al. · Figshare

Diagnostic Pathways and Outcomes of First-Line Atezolizumab plus Bevacizumab in Patients with Locoregional Therapy-Ineligible Hepatocellular Carcinoma at Initial Diagnosis

2026 · Gakushi Komura, Teiji Kuzuya, et al. · Oncology

Clinical Outcomes of Reduced‐Dose Cabozantinib as Third‐ or Later‐Line Therapy After Immune Checkpoint Inhibitors in Advanced Hepatocellular Carcinoma: A Real‐World Study

2025 · Teiji Kuzuya, Hisanori Muto, et al. · Hepatology Research

Successful pancreatectomy after conversion-intended chemotherapy using gemcitabine and nab-paclitaxel for unresectable adenosquamous carcinoma of the pancreas: a case report

2024 · Kenichi Nakamura, Mitsuru Nakagawa, et al. · Surgical Case Reports

Works count: 10

Citation count: 24

H-index: 2

I10-index: 1